Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) constitutes 10–20% of breast cancers and is challenging to treat due to a lack of effective targeted therapies. Previous studies in TNBC cell lines showed in vitro growth inhibition when JQ1 or GSK2801 were administered alone, and enhanced activity wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Yellapu, Nanda Kumar, Ly, Thuc, Sardiu, Mihaela E., Pei, Dong, Welch, Danny R., Thompson, Jeffery A., Koestler, Devin C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173973/
https://www.ncbi.nlm.nih.gov/pubmed/35672711
http://dx.doi.org/10.1186/s12885-022-09690-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173973/
https://www.ncbi.nlm.nih.gov/pubmed/35672711
http://dx.doi.org/10.1186/s12885-022-09690-2

Ejemplares similares